Progress of chondroitin polymerization factor in breast cancer

doi:10.3760/cma.j.issn.1007-1245.2023.09.005

Abstract

Abstract:

Breast cancer is the most common cancer in women worldwide and has become a global health problem. Researches in the latest field of oncology have revealed the potential role of chondroitin polymerization factor (CHPF) in the various biological behaviors of breast cancer. CHPF is a type II transmembrane protein, an enzyme involved in the extension of chondroitin sulfate, and a new key molecule with poor prognosis in many cancers. At present, the mechanism of CHPF in genesis and development of breast cancer has become a research hotspot. In the future, deeply exploring the role of CHPF and its molecular mechanism in breast cancer can provide new ideas for the prevention and treatment and targeted treatment of breast cancer. This paper provides an overview of CHPF and its role in various malignancies, focusing on the biological function of CHPF in breast cancer, which is expected to provide new therapeutic targets for anti-tumor drug research and provide new ideas for tumor treatment.

Key words:

Breast cancer, Chondroitin polymerization factor, Treatment, Prognosis, Biomarkers

摘要：

乳腺癌是全世界女性最常见的癌症，已成为全球性的健康问题。肿瘤学最新领域的研究揭示了软骨素聚合因子（CHPF）在乳腺癌各种生物学行为方面的潜在作用。CHPF是一种Ⅱ型跨膜蛋白，是一种参与硫酸软骨素（chondroitin sulfate，CS）延伸的酶，是许多癌症预后不良的新关键分子。目前，CHPF在乳腺癌发生发展中的机制成为研究热点。未来，深入探究CHPF在乳腺癌中的作用及其分子机制，可为乳腺癌的防治及靶向治疗提供新思路。本文将概述CHPF及其在各种恶性肿瘤中的作用，着重介绍CHPF在乳腺癌中的生物功能，有望为抗肿瘤药物研究提供新的治疗靶点，为肿瘤治疗提供新思路。

关键词:

乳腺癌, 软骨素聚合因子, 治疗, 预后, 生物标志物

Hou Changran, Jiang Jingru, Hua Yitong.

Progress of chondroitin polymerization factor in breast cancer [J]. International Medicine and Health Guidance News, 2023, 29(9): 1201-1204.

侯长冉姜京汝花义同.

软骨素聚合因子在乳腺癌中的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1201-1204.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI: 10.3322/caac.21660.
[2] de Matteis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study[J]. Cancer, 2002, 94(4):895-901. DOI: 10.1002/cncr.20335.abs.
[3] Fisusi FA, Akala EO. Drug combinations in breast cancer therapy[J]. Pharm Nanotechnol, 2019, 7(1):3-23. DOI: 10.2174/2211738507666190122111224.
[4] Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women[J]. Curr Treat Options Oncol, 2019, 20(12):86. DOI: 10.1007/s11864-019- 0685-7.
[5] Izumikawa T, Uyama T, Okuura Y, et al. Involvement of chondroitin sulfate synthase-3 (chondroitin synthase-2) in chondroitin polymerization through its interaction with chondroitin synthase-1 or chondroitin-polymerizing factor[J]. Biochem J, 2007, 403(3):545-552. DOI: 10.1042/BJ20061876.
[6] Hwang S, Mahadevan S, Qadir F, et al. Identification of FOXM1-induced epigenetic markers for head and neck squamous cell carcinomas[J]. Cancer, 2013, 119(24):4249-4258. DOI: 10.1002/cncr.28354.
[7] Hou XM, Zhang T, Da Z, et al. CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway[J]. Pathol Res Pract, 2019, 215(5):988-994. DOI: 10.1016/j.prp.2019.02.005.
[8] Hou XM, Baloch Z, Zheng ZH, et al. Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer[J]. Cancer Manag Res, 2019, 11:3275-3283. DOI: 10.2147/CMAR.S192036.
[9] Kalathas D, Triantaphyllidou IE, Mastronikolis NS, et al. The chondroitin/dermatan sulfate synthesizing and modifying enzymes in laryngeal cancer: expressional and epigenetic studies[J]. Head Neck Oncol, 2010, 2:27. DOI: 10.1186/1758-3284-2-27.
[10] Duan X, Yang J, Jiang B, et al. Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration[J]. Cell Cycle, 2021, 20(5-6):591-602. DOI: 10.1080/15384101.2021. 1890951.
[11] Little PJ, Ballinger ML, Burch ML, et al. Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process[J]. Open Biochem J, 2008, 2:135-142. DOI: 10.2174/1874091X00802010135.
[12] Kitagawa H, Izumikawa T, Uyama T, et al. Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization[J]. J Biol Chem, 2003, 278(26):23666-23671. DOI: 10.1074/jbc.M302493200.
[13] Siebert JR, Conta Steencken A, Osterhout DJ. Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair[J]. Biomed Res Int, 2014, 2014:845323. DOI: 10.1155/2014/845323.
[14] Mizumoto S, Yamada S. An overview of in vivo functions of chondroitin sulfate and dermatan sulfate revealed by their deficient mice[J]. Front Cell Dev Biol, 2021, 9:764781. DOI: 10.3389/fcell.2021.764781.
[15] Nakagawa N, Izumikawa T, Kitagawa H, et al. Sulfation of glucuronic acid in the linkage tetrasaccharide by HNK-1 sulfotransferase is an inhibitory signal for the expression of a chondroitin sulfate chain on thrombomodulin[J]. Biochem Biophys Res Commun, 2011, 415(1):109-113. DOI: 10.1016/j.bbrc.2011.10.023.
[16] Mizumoto S, Yamada S, Sugahara K. Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins[J]. Curr Opin Struct Biol, 2015, 34:35-42. DOI: 10.1016/j.sbi.2015.06.004.
[17] Park SB, Hwang KT, Chung CK, et al. Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer[J]. Clin Exp Metastasis, 2020, 37(6):657-674. DOI: 10.1007/s10585-020-10060-0.
[18] Winship A, Van Sinderen M, Heffernan-Marks A, et al. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration[J]. Int J Oncol, 2017, 50(3):798-804. DOI: 10.3892/ijo.2017.3848.
[19] Svensson KJ, Christianson HC, Kucharzewska P, et al. Chondroitin sulfate expression predicts poor outcome in breast cancer[J]. Int J Oncol, 2011, 39(6):1421-1428. DOI: 10.3892/ijo.2011.1164.
[20] Xu Q, Lin W, Tao C, et al. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells[J]. Biochem Cell Biol, 2020, 98(3):362-369. DOI: 10.1139/bcb-2019- 0227.
[21] Sun W, Zhao F, Xu Y, et al. Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1[J]. Cell Death Dis, 2020, 11(7):496. DOI: 10.1038/s41419-020-2526-9.
[22] Lin X, Han T, Xia Q, et al. CHPF promotes gastric cancer tumorigenesis through the activation of E2F1[J]. Cell Death Dis, 2021, 12(10):876. DOI: 10.1038/s41419-021- 04148-y.
[23] Cao C, Liu Y, Wang Q, et al. Expression of CHPF modulates cell proliferation and invasion in lung cancer[J]. Braz J Med Biol Res, 2020, 53(5):e9021. DOI: 10.1590/1414- 431x20209021.
[24] Schrijver WAME, Suijkerbuijk KPM, van Gils CH, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2018, 110(6):568-580. DOI: 10.1093/jnci/djx273.
[25] Wu T, Dai Y. Tumor microenvironment and therapeutic response[J]. Cancer Lett, 2017, 387:61-68. DOI: 10.1016/j.canlet.2016.01.043.
[26] Reddy SM, Reuben A, Barua S, et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer[J]. Cancer Immunol Res, 2019, 7(6):1025-1035. DOI: 10.1158/2326-6066.CIR-18-0619.
[27] Liao WC, Yen HR, Chen CH, et al. CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment[J]. Am J Cancer Res, 2021, 11(3):812-826.
[28] Ilieva KM, Cheung A, Mele S, et al. Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types[J]. Front Immunol, 2018, 8:1911. DOI: 10.3389/fimmu.2017. 01911.
[29] Mikami T, Kitagawa H. Biosynthesis and function of chondroitin sulfate[J]. Biochim Biophys Acta, 2013, 1830(10):4719-4733. DOI: 10.1016/j.bbagen.2013. 06.006.
[30] Fan YH, Xiao B, Lv SG, et al. Lentivirus‑mediated knockdown of chondroitin polymerizing factor inhibits glioma cell growth in vitro[J]. Oncol Rep, 2017, 38(2):1149-1155. DOI: 10.3892/or.2017.5731.
[31] Li Y, Gong H, Feng L, et al. Chondroitin polymerizing factor promotes breast carcinoma cell proliferation, invasion and migration and affects expression of epithelial-mesenchymal transition-related markers[J]. FEBS Open Bio, 2021, 11(2):423-434. DOI: 10.1002/2211-5463.13062.
[32] Chen X, Zhang Y, Shi Y, et al. MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2[J]. Int J Oncol, 2015, 47(4):1603-1611. DOI: 10.3892/ijo.2015.3143.
[33] Nieto MA. Context-specific roles of EMT programmes in cancer cell dissemination[J]. Nat Cell Biol, 2017, 19(5):416-418. DOI: 10.1038/ncb3520.
[34] Song R, Zhang J, Huang J, et al. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition[J]. Cancer Biomark, 2018, 22(3):565-573. DOI: 10.3233/CBM-181250.